Metformin was first used to treat type 2 diabetes in the late 1950s and in 2022 remains the
first-choice drug used daily by approximately 150 million people. An accumulation of …

Awareness that the metabolic phenotype of cells within tumours is heterogeneous—and
distinct from that of their normal counterparts—is growing. In general, tumour cells …

摘要背景评估在中国人群中糖代谢异常(糖尿病及糖尿病早期) 是否与肿瘤风险增加相关,
并寻找糖代谢异常人群中影响肿瘤风险的因素. 方法2011‐2012 年间, 来自中国大陆地区25 …

Compared with traditional de novo drug discovery, drug repurposing has become an
attractive drug discovery strategy due to its low-cost and high efficiency. Through a …

Cervical and endometrial cancers are among the most dangerous gynaecological
malignancies, with high fatality and recurrence rates due to frequent diagnosis at an …

Obesity and diabetes have both been associated with an increased risk of cancer. In the
face of increasing obesity and diabetes rates worldwide, this is a worrying trend for cancer …

Epidemiological studies suggest associations between diabetes mellitus and some cancers.
The risk of a number of cancers appears to be increased in diabetes mellitus. On the other …

Non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2DM) are common
conditions that regularly co-exist and can act synergistically to drive adverse outcomes. The …

Many anti-diabetic drugs with different mechanisms of action are now available for treatment
of type 2 diabetes mellitus. Sulfonylureas have been extensively used for treatment of type 2 …

Metformin, a prescribed drug for type 2 diabetes, has been reported to have anti-cancer
effects; however, the underlying mechanism is poorly understood. Here we show that this …